Novartis' New Kind of Pharma Deal

Novartis' two-step, $39 billion agreement to take a majority share of eye-group Alcon represents a very new kind of pharma deal: with pharma re-defined to include consumer care and surgery; and, for the first few years at least, with the buyer remaining an arm's length investor.